FDA to Continue to Refuse Entry to Drug Products from Kenebo Facility
The Food and Drug Administration will continue to refuse admission into the U.S. of drug products manufactured at Kanebo Cosmetics’ Odawara Japan facility, the agency said in a warning letter. According to FDA, an inspection found “significant violations of current…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
good manufacturing practice (CGMP) regulations for finished pharmaceuticals.” The agency recommended the company find a third-party consultant with CGMP expertise to assist in bringing the facility into compliance.